A Director at Ultragenyx Pharmaceutical is Exercising Options


Yesterday it was reported that a Director at Ultragenyx Pharmaceutical (RARE), William Aliski, exercised options to sell 7,500 RARE shares at $40.37 a share, for a total transaction value of $559.9K.

This is Aliski’s first transaction since reporting a Buy transaction on AGTC back in December 2018 In addition to William Aliski, one other RARE executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Ultragenyx Pharmaceutical’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $36.31 million and GAAP net loss of -$119,025,000. In comparison, last year the company earned revenue of $18.17 million and had a GAAP net loss of $96.76 million. The company has a one-year high of $76.00 and a one-year low of $31.99. Currently, Ultragenyx Pharmaceutical has an average volume of 458.74K.

Based on 7 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $69.00, reflecting a 3.8% upside.

The insider sentiment on Ultragenyx Pharmaceutical has been positive according to 84 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Read More on RARE:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts